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Abstract
Background: The triple assessment of  clinical breast exam (CBE), fine needle aspirate cytology (FNAC) and breast ultrasonog-
raphy (US) is used in many settings for the diagnosis of  fibroadenoma (FA).  The diagnostic accuracy of  FNAC and US for FA 
in South African (SA) women with palpable breast masses (PBM) is unknown.
Objective:  To report the diagnostic accuracy of  FNAC/US for FA in SA women with PBM. 
Methods:  We conducted a retrospective pilot diagnostic study of  91 women who presented with PBM to a SA regional aca-
demic hospital.  Data for CBE, US, unguided FNAC, and open biopsies was collected from study participant medical records 
and analyzed using diagnostic accuracy tables. 
Results:  A total of  57/91 (62.6%) study participants had uninterpretable FNAC results.  No study participants had uninterpre-
table US results.  The overall diagnostic accuracy of  FNAC for FA was 36.3% (95% Confidence Interval - CI: 27.1-46.5%).  The 
overall diagnostic accuracy of  US for FA was 83.5% (95% CI: 74.6-89.8%).     
Conclusion: The yield of  interpretable test results for FNAC was poor in our study.  The diagnostic accuracy of  US for FA 
appears to be superior to that of  FNAC.  Omission of  FNAC from the triple assessment in our setting should be considered.  .
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Introduction
Fibroadenoma (FA) is the most common palpable be-
nign breast lesion in African women1-8.  The triple assess-
ment is used to investigate for FA and consists of  clinical 
breast examination (CBE), breast ultrasonography (US), 
and fine needle aspirate cytology (FNAC)9,10.  This three 
pronged approach of  investigation results in a diagnostic 
accuracy approaching 100%10.  However, discordant or 
uninterpretable results in one of  the three investigations 
would require that a core needle biopsy (CNB) and sub-
sequent histological analysis be performed10.  The FNAC 
test may yield uninterpretable results for 22-28% of  spec-
imens tested10.  This in turn might result in unwarranted 
CNB, with additional economic consequences for health-
care systems and psychological consequences for afflicted 
patients11,12.  Assessing the accuracy of  FNAC and US for 
the diagnosis of  FA in a South African (SA) setting would 
have important future implications related to health care 
expenditure and resource utilization for benign breast 
disease in SA, and how FA is managed in SA women. 
The objective of  this pilot study was to provide a report 
of  the diagnostic accuracy of  FNAC and US for the de-
tection of  FA in SA women. 
 
Methods
Study design, setting, and study population
This was a retrospective pilot diagnostic accuracy study 
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conducted at the King Edward VIII Hospital (KEH) in 
Durban, SA between 01 January 2012 and 31 December 
2014.  The King Edward VIII hospital is a regional aca-
demic hospital which provides health care services to the 
population residing in parts of  the eThekwini municipali-
ty.  The study population consisted of  a consecutive/con-
venience sample of  91 female participants with palpable 
benign breast masses (PBM) who presented to the surgi-
cal out-patient clinic at KEH during the aforementioned 
study period (ie. we operated on every consecutive patient 
who attended surgical out-patient clinic with a PBM).  All 
participants had a “triple assessment” performed.  As 
per conventional practice for the triple assessment, the 
results of  FNAC and US (as well as CBE) were taken 
together into consideration.  Image-guided CNB is the 
international standard for obtaining histological samples 
for the diagnosis of  breast disease.  However, all patients 
in our study population opted to have the masses excised 
through an open surgical procedure due to cosmetic rea-
sons or fears of  malignancy.  Furthermore, the limited 
availability of  radiological staff  and equipment during the 
study period rendered image-guided CNB unfeasible in 
our specific setting.  Therefore, open biopsy and subse-
quent histological analysis (OBHA) was used as the con-
firmatory diagnostic method in our study.
 
Data collection
Data related to patient age, CBE, US, FNAC, and OBHA 
were collected for each of  the participants included in 
this study using a formal data collection instrument. 
With regard to CBE, the number, size, and location of  
the PBM was recorded for each participant.  Data for US 
and FNAC were broadly classified according to the re-
porting categories used by the UK National Health Ser-
vice Breast Screening Programme (UK-NHSBSP)13.  The 
US and FNAC procedures were performed via an un-
guided approach by trainee radiologists/physicians, un-
der the supervision of  consultant radiologists/physicians. 
While the image guided approach is the recommended 
approach for FNAC in most settings, the availability of  
resources (functioning US machines and radiologists to 
assist with these procedures) at our surgical out-patient 
department was limited during the study period.  There-
fore, FNAC in our setting  had to be performed through 
the unguided approach.  Conventional ultrasonographic 
and cytologic criteria were used to diagnose suspected 
FA.  The open biopsy procedures were performed by 
trainee surgeons under the supervision of  consultant sur-
geons.  Tissue specimens from open biopsies were sent 
to specialist pathology laboratories for analysis.  Conven-
tional histological criteria were used to confirm FA.  Re-
sults from the histological analysis were summarized into 
three categories: FA, other benign lesion, or malignancy. 
In our resource-limited setting it took up to a month after 
CBE to have a US performed, with FNAC performed up 
to a week after US.  The FNAC specimens took up to 
three weeks to be analyzed and reported.  The time peri-
od between receiving a FNAC result and performing an 
open biopsy was four to six weeks.  Histological findings 
from the open biopsy were made available one month 
following the procedure.  Clinical information and results 
from the open biopsy were made available to attending 
physicians.  Clinical information and findings of  the US/
FNAC were not available to the pathologists performing 
the histological assessment.  Data were transferred from 
the data collection instrument to a Microsoft Excel® 
spreadsheet for subsequent statistical analysis.
 
Sample size and statistical analysis
The study population consisted of  91 female participants. 
This sample size was deemed sufficient for this pilot diag-
nostic accuracy study as it exceeds the minimum sample 
size recommended for pilot studies in medical settings14. 
There were no participants in the study population with 
missing test results/reports.  We first conducted a descrip-
tive analysis of  age, CBE, US, FNAC, and OBHA results 
for the study population.  Results for this descriptive anal-
ysis are presented as medians (with interquartile range) or 
frequencies and percentages.  The initial descriptive sta-
tistical analysis was performed in Microsoft Excel® using 
standard formulas/approaches in the software program. 
Measures of  diagnostic accuracy were computed using 
the conventional 2x2 table approach where there were no 
uninterpretable diagnostic test results15. Participants with 
uninterpretable diagnostic tests results were not exclud-
ed from the data analysis.  Rather, the method recom-
mended by Simel and colleagues16 often described as the 
“3x2 table” approach, was used to compute measures of  
diagnostic accuracy where there were uninterpretable di-
agnostic test results.   Sensitivity, specificity, overall test 
yield, likelihood ratios, and diagnostic accuracy in the for-
mat recommended by Simel and colleagues16, with 95% 
confidence intervals (95% CI). The overall reporting of  
our study is in accordance with the 2015 STARD guide-
line17.
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Study ethical approval
The study was given full ethical approval by the Biomedi-
cal Research and Ethics Committee of  The University of  
KwaZulu-Natal (Protocol: BE053/13). 
 
Results
Description of  the study population
The median age of  the study population was 21.0 (18.0-
26.0) years old.  Approximately 60% (n=55/91) of  study 
participants had PBM measuring ≥3cm in size.  The ma-
jority of  study participants presented with a single PBM 
(n=84/91, 92.3%).  Just over half  of  study participants 
had the PBM located on the right breast (n=48/91, 
52.7%).  When stratified according to the reporting cat-
egories used by the UK-NHSBSP, 90 study participants 
(98.9%) had findings of  benign/probable benign lesions 
on US and one participant had findings on US suspicious 
of  malignancy (1.1%).  No OBHA tests were missing and 
no OBHA results were inconclusive.  The main reason 
for why masses were biopsied or removed in our young 
study population was that these masses were found to be 
increasing in size, or were already of  considerable size 
(≥3cm in diameter) and had a negative impact on quali-
ty of  life in afflicted patients.  All histological specimens 
(n=91/91, 100.0%) were diagnosed as benign breast dis-
ease, with 84.6% (n=77/91) of  study participants being 
diagnosed with FA on histology.  When FNAC results 
were stratified according the UK-NHSBSP reporting 
categories, 62.6% (n=57/91) of  participant specimens 
were classified as inadequate, and the remaining 37.4% 
(n=34/91) of  FNAC specimens were classified as be-
nign/probably benign lesions.
 
Description of  FNAC results
The study participant flow for the FNAC test is shown 
in Figure 1.  All study participants had a FNAC test per-
formed.   An interpretable FNAC result was obtained 
for 37.4% of  study participants.  Approximately 3.3% 
(n=3/91) of  study participants tested negative for FA 
on FNAC, and 31.4% (n=31/91) tested positive for FA 
on FNAC.  The remaining 62.6% (n=57/91) of  study 
participants had uninterpretable FNAC test results.  All 
three study participants who tested negative for FA on 
FNAC did not have FA on OBHA.  Of  the study par-
ticipants who tested positive for FA on FNAC (n=31), 
97.8% (n=30/31) had FA confirmed on OBHA, with the 
remaining participant (2.2%) diagnosed with a cyst.  Of  
the participants with uninterpretable FNAC test results 
(n=57), 82.5% (n=47/57) were diagnosed with FA on 
OBHA, and the remaining 17.5% (n=10/57) were diag-
nosed with cystic lesions on OBHA. 
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Figure 1:  Study participant flow diagram – FNAC for the diagnosis of FA 
Description of  US results
The study participant flow for the US test is shown in 
Figure 2.  As with FNAC, all 91 study participants had 
the US test performed.   All study participants had inter-
pretable US results.  Approximately 23.1% (n=21/91) of  
study participants tested negative for FA on US, while the 
remaining 76.9% (n=70/91) of  study participants tested 
positive for FA on US.  All study participants with US 
tests had OBHA performed with interpretable results. 
Almost half  of  the study participants who tested nega-
tive for FA on US (47.6%, n=10/21) did not have FA on 
OBHA.  Of  the study participants who tested positive for 
FA on US (n=70), 94.3% (n=66/70) had FA confirmed 
on OBHA, with the remaining four participants (5.7%) 











FNAC negative for FA
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No FA, n=3/3 (100.0%)
Inconclusive, n=0/3 (0.0%) 
Final diagnosis
FA, n=30/31 (97.8%)
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Figure 2:  Study participant flow diagram – US for the diagnosis of FA 
Cross-tabulation of  test results and measures of  di-
agnostic accuracy
Cross-tabulation of  test results, as well as measures of  di-
agnostic accuracy are shown in Figure.3.  A large propor-
tion of  the study population had uninterpretable FNAC 
test results.  Therefore, the cross-tabulation and associ-
ated measures of  diagnostic accuracy for the FNAC test 
results are presented as a 3x2 diagnostic accuracy table. 
The sensitivity and specificity of  FNAC for FA (ver-
sus OBHA) was 100.0% (95% CI for sensitivity: 88.7-
100.0%) and 75.0% (95% CI for specificity: 30.1-95.4%). 
The positive likelihood ratio for FNAC had a 95% CI 
which overlapped with 1.00.  The negative likelihood ra-
tio for FNAC was 0.00, and we were unable to compute 
the corresponding 95% CIs (No participants were FNAC 
negative and had FA on OBHA).  The likelihood ratio for 
an indeterminate FNAC result was 0.86 (95% CI for like-
lihood ratio: 0.12-1.00).  There were low diagnostic yields 
obtained for FNAC.  The overall diagnostic accuracy of  
FNAC was 36.3% (95% CIfor overall diagnostic accura-
cy: 27.1-46.5%).  The estimated prevalence of  FA in the 
study population based on FNAC was 84.6% (95% CI for 
prevalence estimate: 75.8-90.6%).  There were no unin-
terpretable test results for US, hence cross-tabulation for 
the US test is presented as a conventional 2x2 diagnostic 
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FA (versus OBHA) was 85.7% (95% CI for sensitivity: 
77.9-93.5%) and 71.4% (95% CI for specificity: 47.8-
95.1%).  The positive and negative likelihood ratios for 
US had 95% CIs which did not include 1.00.  The overall 
diagnostic accuracy of  US for FA was 83.5% (95% CI for 
overall diagnostic accuracy: 74.6-89.8%).  The estimated 
prevalence of  FA in the study population based on US 
was 76.9% (95% CI for prevalence estimate: 67.3-84.4%). 
 
*When compared with the “gold standard” of open biopsy and histological analysis. 
US: Breast ultrasonography, FNAC: Fine needle aspirate cytology, FA: Fibroadenoma, CI: Confidence interval, LR+: Positive 
likelihood ratio, LR-: Negative likelihood ratio, LR±: Likelihood ratio for uninterpretable test results, YD+: Positive yield of test, 
YD-: Negative yield of test, UC: Unable to compute, N/A: Not applicable for 2x2 cross-tabulation. 
 
Figure 3:  Cross-tabulation of US and FNAC test results by histology 
findings and estimates of diagnostic accuracy* 
Discussion
Our findings from the CBE suggest that most of  our 
(predominantly young) study population had benign 
breast disease with clinical characteristics commonly as-
sociated with FA18.  Indeed, the OBHA confirmed all 
study participants to have benign breast disease, with the 
vast majority being diagnosed with FA. 
 
While FNAC was performed for all participants in our 
study, interpretable results were only obtained for around 
one-third of  FNAC tests performed.  The high propor-
tion of  uninterpretable results for FNAC is not unique to 
our study10.  The most common reason for uninterpreta-
ble FNAC results is inadequate specimen quality, and it 
is estimated that up to 28% of  FNAC specimens might 
be inadequate10.  By default this leads to the unnecessary 
requirement for OBHA, which has its own economic and 
patient-related consequences.  
 
The poor yield for FNAC had negative consequences on 
measures of  diagnostic accuracy for the test in our study. 
While the sensitivity and specificity for FNAC appear im-
pressive in our study, this should be interpreted cautiously 












FA present             FA absent
Sensitivity, % (95% CI) 85.7 (77.9-93.5) 100.0 (88.7-100.0)
Specificity, % (95% CI) 71.4 (47.8-95.1) 75.0 (30.1-95.4)
LR+, (95% CI) 3.0 (1.3-6.9) 4.00 (0.73-21.84)
LR-, (95% CI) 0.2 (0.1-0.4) 0.00 (UC)
LR±, (95% CI) N/A 0.86 (0.12-1.00)
Overall test yield, % (95% CI) N/A 37.4 (28.1-47.6)
YD+, % (95% CI) N/A 39.0 (28.8-50.1)
YD-, % (95% CI) N/A 28.6 (11.7-54.7)
Accuracy, % (95% CI) 83.5 (74.6-89.8) 36.3 (27.1-46.5)
Disease frequency, % (95% CI) 76.9 (67.3-84.4) 84.6 (75.8-90.6)
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Other studies have also reported high sensitivity and spec-
ificity for FNAC, however these studies differ from ours 
in that they report high diagnostic accuracy for FNAC9,10. 
This can most likely be attributed to the level of  experi-
ence the FNAC operators in our study possessed (as the 
primary operators were trainee physicians), which might 
have been much lower than that of  the FNAC operators 
in other studies.9,10  It could also be that image-guided 
approaches, which were not available in our study, where 
used in these studies.  The confidence intervals for the 
positive likelihood ratio and the likelihood ratio for an 
uninterpretable FNAC test included 1.00.  If  these like-
lihood ratios and confidence intervals are interpreted ac-
cording to the recommendations of  McGee19, we see that 
there is no change in the probability of  FA based on these 
specific test results.  The negative likelihood ratio for 
FNAC was 0.00, however as we were unable to compute 
confidence intervals for this likelihood ratio (possibly as a 
result of  the size of  our study population) it should also 
be interpreted with caution. 
In our study, we found US to have a sensitivity and speci-
ficity similar to that obtained for unguided FNAC (based 
on overlapping confidence intervals).  However, diagnos-
tic accuracy was found to be significantly higher in US 
versus unguided FNAC (based on discrete confidence in-
tervals for estimates for diagnostic accuracy).  The lack of  
uninterpretable results from US tests may have contribut-
ed to the observed diagnostic accuracy.  The confidence 
intervals for the positive and negative likelihood ratios for 
the US test did not include 1.00.  If  the recommendations 
of  McGee19 are applied to these likelihood ratios, we find 
that there is a 20% increase in the probability of  FA be-
ing present if  the US test was positive and a 30% reduc-
tion in the probability of  FA being present if  the US test 
was negative.  The findings of  our study suggests that US 
could be very beneficial for the diagnosis of  FA in this 
setting.  This is also in agreement with the published liter-
ature which reports similar diagnostic accuracy for US9,10. 
However, there is still room for improvement in the over-
all diagnostic accuracy of  83.5% for US.  Furthermore, 
a study by Kemp et al., found that one in ten women 
with benign findings on US had malignancy on histolo-
gy2.  In agreement with the recommendations of  Kemp 
and colleagues2, we propose that “multiple readings” of  
US images should be performed, preferably independent 
readings by radiologists with varying levels of  experience 
(ie. trainee and consultants) to rule out malignancy.  
Although our study shows important individual findings 
for FNAC and US, there are also implications for the 
triple assessment in our setting.  It appears that FNAC 
might be redundant when attempting to diagnose FA in 
a predominantly younger population.  This finding is not 
unique.  A British study by Yue et al., reported that FNAC 
can be omitted in patients <25 years old, particularly 
when CBE and US findings are normal or benign20.  Spe-
cifically, the study of  Yue and colleagues reported that a 
combination of  CBE and US would have avoided needle 
biopsies in all but 3% of  their study population20.  While 
our study findings appear to support those of  Yue et al., 
one must be reminded that our study is a pilot (hypoth-
esis-generating) study, and therefore additional appropri-
ately designed research is required before FNAC can be 
omitted from the FA diagnostic workup in younger SA 
women.  This could result in reduced healthcare expendi-
ture, as well as improved patient satisfaction with the FA 
diagnostic workup.  
 
Limitations  
This patient sample was a consecutive/convenience sam-
ple of  women with PBM who attended a surgical out-
patient clinic at a regional academic SA hospital.  As a 
non-probability sampling method was used, there is a risk 
of  sampling bias in our study.  Future research should 
include sampling methods which reduce the risk of  selec-
tion bias.  In addition, we report data from a single hos-
pital/institution, and our findings might not be generaliz-
able to other hospitals/settings.  Future research should 
involve several hospitals/institutions.  We do not present 
data on familial history of  breast disease or HIV infec-
tion.  However, these variables have not been shown to 
be associated with benign breast disease elsewhere2, and 
this validates their exclusion from this analysis.  Our study 
sample size might appear modest (although adequate for 
the purposes of  a pilot diagnostic study), however it is 
still larger than the sample size of  the study by Kemp and 
colleagues.  Our study population lacked participants with 
malignant disease and so the potential impact of  malig-
nancy on US and FNAC performance for FA diagnosis 
in our setting could not be investigated.  We recommend 
further research with a larger sample size to adequately 
investigate the impact of  malignancy on the diagnostic 
accuracy of  US and FNAC for FA.  Both FNAC and US 
are operator dependent.  Due to resource constraints at 
our institution during the study period, all FNAC proce-
dures were performed through the unguided approach. It 
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is possible that the yield of  FNAC tests with interpretable 
results might be increased through an image-guided ap-
proach in SA settings, though this would require further 
investigation. Finally, in our study only the US reports, 
and not the ultrasound images themselves, were available 
for interpretation.  Therefore we were unable to present 
US imaging data outside that which was contained within 
the diagnostic reports.  This limitation can only be ad-
dressed through prospectively designed studies, where 
additional copies of  these imaging results are obtained 
for research purposes.  While our study does have several 
limitations, we believe that it is an important study from 
a SA setting which provides preliminary information re-
lated to the diagnostic accuracy of  FNAC and US for FA, 
particularly as we included uninterpretable results in our 
analysis.  In general, these uninterpretable test results are 
often excluded or incorrectly assigned to other diagnostic 
outcome categories.
 
Breast ultrasonography had a much higher diagnostic ac-
curacy for FA than unguided FNAC.  Multiple readings 
might further improve the diagnostic accuracy of  US. 
Our findings suggest that FNAC might not be necessary 
as part of  the diagnostic workup for FA in some settings. 
We recommend further research be conducted to con-
firm our findings and address the limitations of  our study.
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